Riskpilot← Back to searchSign inGet full accessPHARMADIRECT A/S
A/SDissolvedCVR 34221138Mimersvej 4Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20121 employees
Revenue 2022
DKK -10K
+54% vs 2021
EBITDA margin
100.0%
-54% vs 2021
Equity ratio
99.3%
Financial strength
Net profit 2022
DKK -29K
-6% vs 2021
| Revenue | DKK -10K | +54% |
| EBITDA | DKK -10K | -54% |
| Net profit | DKK -29K | -6% |
| Total assets | DKK 2,4M | -1% |
| Equity | DKK 2,4M | -1% |
| Employees | 1 | — |
Legal name
PHARMADIRECT A/S
CVR number
34221138
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
25. januar 2012
Share capital
DKK 2.424.791
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening eller af 2 bestyrelsesmedlemmer i forening.
Address
Mimersvej 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -18 | -40 | -92 | -1.981 | -12 | -4 | -6 | -6 | -7 | -6 | -10 |
| Staff expenses | -0 | -0 | -693 | -1.600 | -299 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -18 | -40 | -785 | -3.580 | 286 | -4 | -6 | -6 | -7 | -6 | -10 |
| Depreciation & amort. | -0 | -0 | -94 | -180 | -32 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -18 | -40 | -878 | -3.761 | 254 | -4 | -6 | -6 | -7 | -6 | -10 |
| Net financials | 0 | 0 | 196 | 139 | 2 | -9 | -15 | -15 | -16 | -21 | -19 |
| Profit before tax | -18 | -40 | -683 | -3.621 | 256 | -13 | -21 | -21 | -23 | -27 | -29 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -18 | -40 | -683 | -3.621 | 256 | -13 | -21 | -21 | -23 | -27 | -29 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 487 | 452 | 19.889 | 3.084 | 2.551 | 2.536 | 2.516 | 2.495 | 2.472 | 2.446 | 2.427 |
| Equity | 482 | 442 | 19.759 | 2.288 | 2.544 | 2.531 | 2.510 | 2.489 | 2.467 | 2.439 | 2.410 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 10 | 129 | 796 | 6 | 5 | 6 | 6 | 6 | 7 | 17 |
| Total debt | 5 | 10 | 129 | 796 | 6 | 5 | 6 | 6 | 6 | 7 | 17 |
EBITDA margin
-1000000.0%
This company
15.8%
Market median
-6329214% vs market
20122022
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20122022
Return on equity
-1.2%
This company
18.4%
Market median
-107% vs market
20122022
Net profit margin
-2903400.0%
This company
8.1%
Market median
-35844544% vs market
20122022
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20122022
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20122022
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-25 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GF Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
JM Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
SR Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
PJ Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
CD Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
JU Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2013 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FONDEN DBK | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMADIRECT A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gert Frost | Chief Executive Officer | 0 companies |
| Janus Mark Erwolter | Chief Executive Officer | 0 companies |
| Søren Riis Jensen | Chief Executive Officer | 0 companies |
| Peter Johnsen | Chief Executive Officer | 0 companies |
| Carsten Dalbo Pedersen | Chief Executive Officer | 0 companies |
| Jan Ulrich Hjorth-Gravesen | Chief Executive Officer | 0 companies |
| Berit Hoelgaard Didriksen | Board of Directors | 0 companies |
| Jørgen Clausen | Chairman | 0 companies |
| Karsten Engdahl | Chairman | 0 companies |
| Ejvind Sandal | Board of Directors | 0 companies |
| Hans Henrik Raith | Board of Directors | 0 companies |
| Hans Christian Korsgård Madsen | Chairman | 0 companies |
| Aksel Emanuel Bjørke | Board of Directors | 0 companies |
| Hans Peter Nordstrøm Nissen | Chairman | 0 companies |